accountCharles River Laboratories International has agreed to terminate its $1.6 billion proposed takeover of WuXi PharmaTech, a Chinese drug research and development outsourcing company. Charles River will pay WuXi a $30 million break-up for the privilege, $5...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Lessons from the End of the Charles River Deal
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account